NASDAQ
5.46USD
+0.04 (+0.74%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
110.9M
P/E
—
EPS
—
Beta
1.43
52W range
3.5-5.84
Day range
5.38–5.56
Open
5.38
Prev close
5.42
Volume
100.4K
Avg volume
178.1K
Dividend
0.00
IPO
2020-06-26
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about PolyPid Ltd. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PYPD: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
